32 Hikma PHarmaceuticals Plc annual report 2011 BusI n E s s a n d f I na nC I a l R E V I E W pRInCIpal RIsks and unCERtaIntIEs tHE GROups BusInEss faCEs RIsks and unCERtaIntIEs the section below includes the principal risks and uncertainties that the Group considers could have a significant effect on its financial condition, results of operations or future performance.
the list is not set out in order of priority and other risks, currently unknown or not considered material, could have a similar effect.
OpERatIOnal RIsks risk PoteNtial imPact mitiGatioN Compliance with regulatory requirements delays in supply or an inability to Commitment to maintain the market or develop the Groups products highest levels of quality across failure to comply with applicable allmanufacturing facilities regulatory requirements delayed or denied approvals for the and manufacturing standards introduction of new products strong global compliance function often referred to as Current Good that oversees across theGroup product complaints or recalls manufacturing practices or cGmp Remuneration and reward structure Bans on product sales or importation that helps retain experienced personnel disruptions to operations Continuous staff training and potential for litigation know-how exchange On-going development of standard operating procedures Regulation changes Restrictions on the sale of one or strong oversight of local regulatory more of our products environments to help anticipate unanticipated legislative and potential changes regulatory actions, developments Restrictions on our ability to sell and changes affecting the ourproducts at a profit local operations in all of our key markets Groups operations and products unexpected additional costs required Representation and or affiliation to produce, market orsellour products with local industry bodies Increased compliance costs diverse geographical and therapeutic business model Commercialisation of new products slowdown in revenue growth Experienced regulatory teams able to from new products accelerate submission processes across delays in the receipt of marketing all of our markets approvals, the authorisation of price Inability to deliver a positive and reimbursement returnon investments in Highly qualified sales and marketing R&d, manufacturing and sales teams across all markets lack of approval and acceptance of and marketing new products by physicians, patients a diversified product pipeline with173 new and other key decision-makers compounds pending approval, covering a broad range oftherapeutic areas Inability to confirm safety, efficacy, convenience and or cost-effectiveness a systematic commitment to quality of our products as compared to that helps to secure approval and competitive products acceptance of newproducts and mitigate potential safety issues Inability to participate in tender sales BusiNess aNd fiNaNcial review 33 Hikma PHarmaceuticals Plc annual report 2011 OpERatIOnal RIsks COntInuEd risk PoteNtial imPact mitiGatioN Product safety Interruptions to revenue flow diversification of product portfolio across key markets and therapies unforeseen product safety issues Costs of recall, potential for litigation for marketed products, particularly Working with stakeholders to understand Reputational damage in respect of in-licensed products issues as they arise Product development Inability to grow sales and increase Experienced and successful in-house profitability for the Group R&d team, with specifically targeted failure to secure new products or product development pathways compounds for development lower return on investment in research and development Continually developing and multi-faceted approach to new product development strong business development team track record of building in-licensed brands position as licensee of choice for our key mEna geography Co-operation with Third parties loss of products from our portfolio Investment in long-term relationships with existing in-licensing partners Inability to renew or extend Revenue interruptions in-licensing or other co-operation Experienced legal team capable of failure to recoup sales and marketing agreements with third parties negotiating robust agreements with our and business development costs partners Continuous development of new partners for licensing and co-operation diverse revenue model with in-house R&d capabilities Increased competition loss of market share On-going portfolio diversification, differentiation and renewal through new market entrants in key decreasing revenues on internal R&d, in-licensing and geographies established portfolio product acquisition On-going pricing pressure in Continuing focus on expansion of increasingly commoditised markets geographies and therapeutic areas Disruptions in the manufacturing Inability to develop and or alternate approved suppliers of supplychain commercialise new products active ingredients Inability to procure apI Inability to market existing long-term relationships with reliable fromapprovedsources products as planned raw material suppliers Inability to procure apI on lost revenue streams on short notice Corporate auditing team  continuously monitors regulatory Reduced service levels and damage compliance of apI suppliers Inability to procure the quantities of to customer relationships apIneeded to meet market requirements focus on improving service levels Inability to supply finished product and optimising our supply chain to our customers in a timely fashion 34 Hikma PHarmaceuticals Plc annual report 2011 BusInEss and fInanCIal REVIEW Operational risks continued OpERatIOnal RIsks COntInuEd risk PoteNtial imPact mitiGatioN Economic and political and unforeseenevents disruptions to manufacturing Geographic diversification, with andmarketing plans nine manufacturing facilities and sales The failure of control, a change inthe in more than 40 countries economic conditions or political lost revenue streams environment or sustained civil unrest product diversification, with 667 products Inability to market or supply products in any particular market or country and 1,598 dosage strengths and forms unforeseen events such as fire or flooding could cause disruptions to manufacturing or supply Litigation financial impact on Group results In-house legal counsel with relevant from adverse resolution of proceedings jurisdictional experience Commercial, product liability and other claims brought against Reputational damage the Group fInanCIal RIsks risk PoteNtial imPact mitiGatioN Foreign exchange risk fluctuations in the Groups net Entering into currency derivative asset values and profits upon contracts where possible Exposure to foreign exchange translation into us dollars movements, primarily in the Euro, foreign currency borrowing algerian dinar, sudanese pound matching foreign currency revenues and Egyptianpound to in-jurisdiction costs Interest rate risk fluctuating impact on profits Optimisation of fixed and variable rate before taxation debt as a proportion of our total debt Volatility in interest rates use of interest rate swap agreements Credit risk Reduced working capital funds Clear credit terms for settlement of sales invoices Inability to recover trade receivables Risk of bad debt or default Group credit policy limiting credit Concentration of significant trade exposures balances with key customers in the mEna region and the us use of various financial instruments such as letters of credit, factoring and credit insurance arrangements Liquidity risk Reduced liquidity and working Continual evaluation of headroom capital funds and borrowing Insufficient free cash flow and borrowings headroom Inability to meet short-term working Committed debt facilities capital needs and, therefore, to execute diversity of institution, subsidiary and our long-term strategic plans geography of borrowings Tax negative impact on the Groups Close observation of any intended or effective tax rate proposed changes to tax rules, both Changes to tax laws and regulations in the uk and in other key countries in any of the markets in which we operate Costly compliance requirements where the Group operates BusiNess aNd fiNaNcial review 35 Hikma PHarmaceuticals Plc annual report 2011 Basis of preparation and materially from those expressed or implied bythe forward-looking statements, and  this business and financial review has been should be treated with caution.
these risks, uncertainties or assumptions could adversely prepared solely to provide additional information to shareholders to assess the affect the outcome and financial effects of theplans and events described in this review.
companys strategies and the potential for those strategies to succeed, and should not be forward-looking statements contained in this review regarding past trends or activities relied on by any other party or for any other purpose.
certain statements in the above should not be taken as a representation that such trends or activities will continue in the review are forward-looking statements usingwords such as intends, believes, future.
you should not place undue reliance on forward-looking statements, which speak as anticipates and expects.
where included, these have been made by the directors in only of the date of the approval of this report except as required by law, the company good faith based on the information available to them up to the time of their approval of this is under no obligation to update or keep current the forward-looking statements report.
By their nature, forward-looking statements are based on assumptions and contained in this review or to correct any inaccuracies which may become apparent in involve inherent risks and uncertainties that could cause actual results or events to differ such forward-looking statements.
36 Hikma PHarmaceuticals Plc annual report 2011 sustainability 37 Hikma PHarmaceuticals Plc annual report 2011 sustainability SuStainable Quality 38 enSuring the SuStainability of our buSineSS
